ADMA Biologics (ADMA) Misses Q2 EPS by 1c

ADMA Biologics (NASDAQ: ADMA) reported Q2 EPS of $0.14, $0.01 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $121.98 million versus the consensus estimate of $124.13 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• Deere conference call: 2027 orders up mid-single digits from last year)
• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• China semiconductor equipment imports grow 9% in July, Barclays comments